Clinical Trials Logo

Advanced Breast Cancer clinical trials

View clinical trials related to Advanced Breast Cancer.

Filter by:

NCT ID: NCT05655598 Recruiting - Bladder Cancer Clinical Trials

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

Start date: September 12, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: - Patients with advanced breast cancer that has become worse after taking palbociclib alone - Patients with cancers that have an abnormality in a gene called the "retinoblastoma gene".

NCT ID: NCT05654623 Recruiting - Clinical trials for Advanced Breast Cancer

A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.

VERITAC-2
Start date: March 3, 2023
Phase: Phase 3
Study type: Interventional

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

NCT ID: NCT05631795 Recruiting - Clinical trials for Advanced Breast Cancer

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

ALPINIST
Start date: August 9, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with HR-positive, HER2-negative, advanced or metastatic breast cancer (aBC) with a PIK3CA mutation, whose disease has progressed on or after endocrine-based treatment

NCT ID: NCT05594095 Recruiting - Breast Cancer Clinical Trials

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Start date: December 30, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision therapy in patients hormone-receptor-positive HER2-negative advanced breast cancer who had previously used CDK4/6 inhibitors.

NCT ID: NCT05530057 Recruiting - Clinical trials for Advanced Breast Cancer

Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer

ESPERO
Start date: February 18, 2020
Phase: Phase 2
Study type: Interventional

Optimal salvage treatment for HER2-positive breast cancer after trastuzumab and T-DM1 failure still remains to be established. We would like to investigate the efficacy and safety of combination chemotherapy of eribulin and trastuzumab as salvage treatment for HER2-Positive breast cancer after exposure to trastuzumab and T-DM1

NCT ID: NCT05508906 Recruiting - Clinical trials for Metastatic Breast Cancer

Phase 1b Combo w/ Ribociclib and Alpelisib

Start date: August 31, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation).

NCT ID: NCT05452213 Recruiting - Breast Cancer Clinical Trials

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

CAPTOR-BC
Start date: October 12, 2022
Phase: Phase 4
Study type: Interventional

This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with ribociclib and standard of care endocrine treatment according to SmPC.

NCT ID: NCT05439499 Recruiting - Clinical trials for Advanced Breast Cancer

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Start date: March 2, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of FCN-437c in combination with letrozole or anastrozole ± Goserelin versus placebo combined with letrozole or anastrozole ± Goserelin in women with first-line advanced breast cancer in HR+ and HER2-.

NCT ID: NCT05438810 Recruiting - Clinical trials for Advanced Breast Cancer

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Start date: January 18, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled Phase iii clinical study evaluating the efficacy and safety of FCN- 437c in combination with fluvestrant ± goseraline versus placebo in combination with fluvestrant ± goseraline in women with HR+ and HER2- advanced breast cancer.

NCT ID: NCT05424068 Recruiting - Clinical trials for Advanced Breast Cancer

Rehabilitation for People With Advanced Cancer

Start date: December 2, 2022
Phase: N/A
Study type: Interventional

The proposed study is a Phase II, feasibility, randomized controlled preference based study. This will be conducted in Vancouver and Toronto and includes breast and colorectal cancers.